ALK-Abelló A/S (AKBLF) Stock

About ALK-Abelló A/S

Established in 1923 and headquartered in Hørsholm, Denmark, ALK-Abelló A/S is a global pharmaceutical enterprise specializing in allergy treatment. The company provides a comprehensive range of allergy solutions to markets across Europe, North America, and other international regions. These offerings include immunotherapy products delivered through injections, sublingual drops, and oral tablets, designed to address various allergies such as those caused by house dust mites, grass, tree, ragweed, and Japanese cedar. ALK-Abelló also manufactures adrenaline auto-injectors for the critical management of severe allergic reactions and produces diagnostic tools essential for identifying allergic conditions. Their product portfolio features notable treatments like GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX, all aimed at allergic rhinitis, as well as ACARIZAX, which targets both allergic rhinitis and allergic asthma.

ALK-Abelló A/S is headquartered in DK.

ALK-Abelló A/S (AKBLF) stock trades at $37.92 with a market capitalization of $7.63B. The stock is valued at a price-to-earnings (P/E) ratio of 40.69, price-to-book of 7.92, price-to-sales of 7.93. Over the past 52 weeks the stock has ranged between $28.95 and $40.65, and currently trades 6.7% below its 52-week high. It pays a dividend yielding 0.63%.

On profitability, ALK-Abelló A/S generates a return on equity (ROE) of 20.45% — well above the market average, a sign of a high-quality business, return on capital employed of 22.33%, an operating margin of 26.73%, a net profit margin of 19.51%.

Official website: www.alk.net